Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Birte Kulemann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0278-7874; OpenAlex author ID A5039810811. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 1 paper

Papers 11

  1. [Incidence, Treatment and Survival in Pancreatic Cancer- Data of the Nationwide Oncological Quality Conference from a Surgical Perspective]. Co-author DOI 10.1055/a-1768-1012↗
  2. Postoperative Outcomes of Tangential versus Segmental Resection and End-to-end Reconstruction of the Superior Mesenterico-Portal Vein During Pancreatoduodenect… Co-author DOI 10.21873/anticanres.15329↗
  3. ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.12426↗
  4. Extended pancreatic head resection for pancreatic cancer in the presence of a circumportal pancreas. Co-author DOI 10.1111/ans.14015↗
  5. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Last author DOI 10.3390/cancers11111659↗
  6. [Circulating tumor cells in pancreatic cancer : Results of morphological and molecular analyses and comparisons with the primary tumor]. Co-author DOI 10.1007/s00292-018-0550-7↗
  7. Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Co-author DOI 10.1038/s41598-017-04601-z↗
  8. Author Correction: Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Co-author DOI 10.1038/s41598-017-14870-3↗
  9. Pregnancy Specific β-1 Glycoprotein 1 is Expressed in Pancreatic Ductal Adenocarcinoma and its Subcellular Localization Correlates with Overall Survival. Co-author DOI 10.7150/jca.15864↗
  10. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000324↗
  11. Sonic Hedgehog in pancreatic cancer: from bench to bedside, then back to the bench. Co-author DOI 10.1016/j.surg.2012.05.030↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jens Hoeppner · 8 shared papers, 2015–2021 · strength 0.74
  2. Ulrich Friedrich Wellner · 3 shared papers, 2016–2022 · strength 0.30
  3. Tobias Keck · 2 shared papers, 2021–2022 · strength 0.25
  4. Hryhoriy V. Lapshyn · 2 shared papers, 2021–2022 · strength 0.25
  5. Louisa Bolm · 2 shared papers, 2021–2022 · strength 0.25
  6. Rüdiger Braun · 2 shared papers, 2021–2022 · strength 0.25
  7. Steffen Deichmann · 2 shared papers, 2021–2022 · strength 0.25
  8. Kim C. Honselmann · 2 shared papers, 2021–2022 · strength 0.25
  9. Verena Martini · 3 shared papers, 2017–2019 · strength 0.24
  10. Jens Höppner · 2 shared papers, 2018–2022 · strength 0.24
  11. Sylvia Timme‐Bronsert · 2 shared papers, 2018–2019 · strength 0.23
  12. Martha B. Pitman · 3 shared papers, 2015–2017 · strength 0.17
  13. Dirk Bausch · 2 shared papers, 2012–2021 · strength 0.14
  14. Oliver Schilling · 2 shared papers, 2016–2019 · strength 0.13
  15. Sylvia Timme · 2 shared papers, 2017 · strength 0.12
  16. Saskia Hussung · 2 shared papers, 2017 · strength 0.12
  17. Heiko Becker · 2 shared papers, 2017 · strength 0.12
  18. Ralph Fritsch · 2 shared papers, 2017 · strength 0.12
  19. Ekaterina Petrova · 1 shared paper, 2021 · strength 0.11
  20. Natalie Petruch · 1 shared paper, 2021 · strength 0.11
  21. Dirk Rades · 1 shared paper, 2021 · strength 0.11
  22. Victor Oginga Oria · 1 shared paper, 2019 · strength 0.09
  23. Jörg Walter Bartsch · 1 shared paper, 2019 · strength 0.09
  24. Nakul P. Valsangkar · 2 shared papers, 2012–2015 · strength 0.08
  25. Sarah P. Thayer · 2 shared papers, 2012–2015 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.